References

Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review

10.7326/m17-2073 · 2018 · External reference

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis

10.1186/s40425-018-0461-4 · 2018 · External reference

10.1186/s41073-019-0064-8 · 2019 · Admitted local publication

Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis

10.1001/jamaoncol.2017.3064 · 2018 · External reference

Development of the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

10.1093/jnci/dju244 · 2014 · External reference

Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment

10.1001/jama.2017.7156 · 2017 · External reference

Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial

10.1001/jama.2022.9265 · 2022 · External reference

Validity and reliability of the U.S. national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events

10.1001/jamaoncol.2015.2639 · 2015 · External reference

Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer

10.1001/jamaoncol.2019.0402 · 2019 · External reference

Society for immunotherapy of cancer clinical practice guideline on immune checkpoint inhibitor-related adverse events

10.1136/jitc-2021-002435 · 2021 · External reference

Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors

10.1007/s40262-019-00748-2 · 2019 · External reference

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

10.1093/annonc/mdx108 · 2017 · External reference

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

10.1016/j.kint.2016.04.008 · 2016 · External reference

Delayed immune-related events after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

10.1186/s40425-019-0645-6 · 2019 · External reference

Neurological adverse events associated with immune checkpoint inhibitors: review of the literature

10.1016/j.ejca.2016.12.001 · 2017 · External reference

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors

10.1007/s00520-023-07934-w · External reference

Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes: protocol for a randomized phase II controlled trial

10.2196/48386 · External reference

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

10.1172/jci96798 · 2018 · External reference

Management of pulmonary toxicity associated with immune checkpoint inhibitors

10.1183/16000617.0012-2019 · 2019 · External reference

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline

10.1016/j.annonc.2022.04.007 · 2022 · External reference

Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer

10.1001/jamaoncol.2020.0726 · 2020 · External reference

Late-onset immune-related adverse events after immune checkpoint inhibitor therapy

10.1001/jamanetworkopen.2025.2668 · 2025 · External reference

Unresolved reference

2017 · External reference

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update

10.1136/jitc-2023-008591 · 2024 · External reference

Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data

10.1136/jitc-2025-012823 · 2026 · External reference

Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance

10.1146/annurev-pharmtox-022820-093805 · 2021 · External reference

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

10.1136/jitc-2021-002890 · 2021 · External reference

Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2022.10.001 · 2022 · External reference

SBAR: a shared mental model for improving communication between clinicians

10.1016/s1553-7250(06)32022-3 · 2006 · External reference

Effectiveness of electronic patient-reported outcomes in patients with cancer undergoing immunotherapy: a real-world retrospective study

10.1007/s10147-026-03032-z · 2026 · External reference

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

10.1093/annonc/mdx286 · 2017 · External reference

Co-design of an electronic patient-reported outcome symptom monitoring system for immunotherapy toxicities

10.1007/s00520-024-09034-9 · 2024 · External reference

Patient-reported outcome measure (PROM) programs for monitoring symptoms among patients treated with immunotherapy: a scoping review

10.1093/jncics/pkae102 · 2024 · External reference

Focusing on digital health equity

10.1001/jama.2021.18459 · 2021 · External reference

Myocarditis in patients treated with immune checkpoint inhibitors

10.1016/j.jacc.2018.02.037 · 2018 · External reference

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

10.1038/s41571-019-0218-0 · 2019 · External reference

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

10.1016/j.cell.2021.09.020 · 2021 · External reference

Society for immunotherapy of cancer consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events terminology

10.1136/jitc-2022-006398 · 2023 · External reference

Unresolved reference

2017 · External reference

Unresolved reference

2026 · External reference

Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase

10.1136/jitc-2024-009902 · 2024 · External reference

Immune checkpoint inhibitors and myocarditis-myositis-myasthenia gravis overlap: a FAERS pharmacovigilance study with time-to-onset characterization

10.3389/fphar.2026.1825269 · 2026 · External reference

Network analysis of the multidimensional symptom experience of oncology

10.1038/s41598-018-36973-1 · 2019 · External reference

Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma

10.1001/jamaoncol.2021.0051 · 2021 · External reference

An integrative review of adult cancer patients' experiences of nursing telephone and virtual triage systems for symptom management

10.1016/j.ejon.2023.102428 · 2023 · External reference

Immune-related adverse events associated with immune checkpoint blockade

10.1056/nejmra1703481 · 2018 · External reference

Immune-related adverse events of checkpoint inhibitors

10.1038/s41572-020-0160-6 · 2020 · External reference

Immune checkpoint inhibitor-related myocarditis reported through the FDA adverse event reporting system: pharmacovigilance trends in reporting and outcomes

10.3389/fonc.2025.1498817 · 2025 · External reference

Digital inclusion as health care-supporting health care equity with digital-infrastructure initiatives

10.1056/nejmp2115646 · 2022 · External reference

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

10.1016/s1470-2045(18)30608-9 · 2018 · External reference

Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design

10.1016/j.acvd.2024.12.005 · 2025 · External reference

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update

10.1200/jco.21.01440 · 2021 · External reference

The effect of nurse-led remote telephone triage on symptom management of patients with cancer: a systematic review and meta-analysis

10.1111/wvn.12721 · 2024 · External reference

Clinical pharmacology considerations for the development of immune checkpoint inhibitors

10.1002/jcph.990 · 2017 · External reference

Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy

10.1007/s40257-017-0336-3 · 2018 · External reference

Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer

10.1001/jamaoncol.2019.1022 · 2019 · External reference

Development and evaluation of evidence-informed clinical nursing protocols for remote assessment, triage and support of cancer treatment-induced symptoms

10.1155/2013/171872 · 2013 · External reference

Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

10.1038/s43018-023-00572-5 · 2023 · External reference

Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors

10.1016/j.jtho.2018.08.2035 · 2018 · External reference

NCCN guidelines insights: management of immunotherapy-related toxicities, version 2.2024

10.6004/jnccn.2024.0057 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study

10.1016/s1470-2045(24)00278-x · 2024 · External reference

Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis

10.1001/jamaoncol.2018.3923 · 2018 · External reference

Unresolved reference

2026 · External reference

Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning

10.1111/bph.70195 · 2026 · External reference

Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial

10.1001/jamanetworkopen.2022.4427 · 2022 · External reference

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

10.1136/jitc-2021-003277 · 2021 · External reference